EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combined Plasmid Redesign and Transfection Optimization Significantly Increases Upstream AAV Titers While Maintaining Vector Quality and In Vivo Potency

Shiliang Hu, Yinxing Chen, Carmen Wu, Wilhad Hans Reuter, June Deng, Nannan Jia, Noel Walsh, Amy Bastille, Thomas M Edwards, Matthias Hebben iD, Nelson Chau, Jing Liao

Microorganisms · 20.08.2026 · 14 (8) · 1857

DOI: 10.3390/microorganisms14081857 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microorganisms, online erschienen am 20.08.2026. Verfasst von Shiliang Hu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Genomic Medicine, Alexion, AstraZeneca Rare Disease, 100 Binney Street, Cambridge, MA 02142, USA. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A high manufacturing cost of goods (CoG) remains a critical barrier to the broad clinical adoption of gene therapies and is driven in part by limited productivity in adeno-associated virus (AAV) manufacturing. Here, we report an optimized AAV production process developed to markedly increase upstream titers while preserving vector quality and potency. The process combines a redesigned plasmid system, an optimized plasmid ratio, and a novel synthetic transfection reagent and was benchmarked against a conventional triple-plasmid/PEI MAX workflow. Across multiple AAV capsids and independent production runs, the optimized process reproducibly increased crude harvest titers by approximately 10- to 33-fold relative to the standard process, while maintaining key vector quality attributes. Notably, within the detection limits of the assay, rcAAV was undetectable at 1 × 1010 vg input with the optimized process, whereas the conventional triple-plasmid (with native Rep-Cap sequence)/PEI MAX workflow remained rcAAV-positive under identical conditions. Importantly, the in vivo potency was comparable to that of vectors produced by the conventional process. These results position our optimized AAV production process as a promising strategy to materially reduce AAV manufacturing CoG per patient.

Schlagwörter

Stichwörter der Autor:innen

AAV production processreplication-competent AAV (rcAAV)two-plasmid system (2P)

Autor:innen und Institutionen

  • Genomic Medicine, Alexion, AstraZeneca Rare Disease, 100 Binney Street, Cambridge, MA 02142, USA.
  • LogicBio Therapeutics, 65 Hayden Avenue, Lexington, MA 02421, USA.

ORCID-Profile: Matthias Hebben

Zitieren

APA

Hu, S., Chen, Y., Wu, C., Reuter, W. H., Deng, J., Jia, N., Walsh, N., Bastille, A., Edwards, T. M., Hebben, M., Chau, N., & Liao, J. (2026). Combined Plasmid Redesign and Transfection Optimization Significantly Increases Upstream AAV Titers While Maintaining Vector Quality and In Vivo Potency. Microorganisms, 14(8), 1857. https://doi.org/10.3390/microorganisms14081857

Vancouver

Hu S, Chen Y, Wu C, Reuter WH, Deng J, Jia N, et al. Combined Plasmid Redesign and Transfection Optimization Significantly Increases Upstream AAV Titers While Maintaining Vector Quality and In Vivo Potency. Microorganisms. 2026;14(8):1857. doi:10.3390/microorganisms14081857

BibTeX
@article{Hu2026,
  author = {Hu, Shiliang and Chen, Yinxing and Wu, Carmen and Reuter, Wilhad Hans and Deng, June and Jia, Nannan and Walsh, Noel and Bastille, Amy and Edwards, Thomas M and Hebben, Matthias and Chau, Nelson and Liao, Jing},
  title = {Combined Plasmid Redesign and Transfection Optimization Significantly Increases Upstream AAV Titers While Maintaining Vector Quality and In Vivo Potency},
  journal = {Microorganisms},
  year = {2026},
  volume = {14},
  number = {8},
  pages = {1857},
  doi = {10.3390/microorganisms14081857}
}
Kostenlos starten →